LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) Files An 8-K Other Events
Item 8.01. Other Events.

On May 16, 2018, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its intention to offer $650.0 million aggregate principal amount of its convertible senior notes due 2023 in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Offering”). On May 18, 2018, the Company issued a press release announcing the pricing of the Offering of $650 million aggregate principal amount of 0.75% convertible senior notes due 2023. Copies of the press releases are filed herewith as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

LIGAND PHARMACEUTICALS INC Exhibit
EX-99.1 2 projectlighthouse-pricingp.htm EXHIBIT 99.1 Exhibit Exhibit 99.2Contacts: Ligand Pharmaceuticals IncorporatedLHA Investor RelationsTodd PettingillBruce [email protected]@lhai.com858 550-7893310 691-7100Ligand Prices Offering of $650 Million of Convertible Senior NotesSAN DIEGO (May 18,…
To view the full exhibit click here

About LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND)

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.